Dr. Strosberg on Understanding the Current Field of Neuroendocrine Tumors

Jonathan R. Strosberg, MD
Published: Friday, May 26, 2017



Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, shares his insight on the current field of neuroendocrine tumors (NETs).

After years of everolimus (Afinitor) and metastin analogs, the field is in a stage of expansion, says Strosberg. Agents such as telotristat ethyl (Xermelo) are signifying that new drugs—although niche—are signaling advancement in the treatment of NETs.
 


Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, shares his insight on the current field of neuroendocrine tumors (NETs).

After years of everolimus (Afinitor) and metastin analogs, the field is in a stage of expansion, says Strosberg. Agents such as telotristat ethyl (Xermelo) are signifying that new drugs—although niche—are signaling advancement in the treatment of NETs.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Navigating New Sequencing Challenges for the Treatment of Hepatocellular CarcinomaAug 30, 20191.5
Publication Bottom Border
Border Publication
x